Research

Interviews with parents from underrepresented communities found that nearly all were interested in newborn genomic sequencing, showing broad family demand for the kind of screening Fore offers. It also stresses clear communication and access, which is why Fore delivers every result with genetic counseling.

This review summarizes large studies showing genomic newborn screening detects many more treatable conditions than standard panels, with high parental acceptance. It reflects the growing evidence base behind Fore’s screen for 1,000+ conditions beyond the state panel.

The authors set out how to measure the clinical and economic value of genomic testing as it moves into mainstream care. Their framework supports the case that proactive genomic screening like Fore’s creates value through earlier, better-informed health decisions.

This ethics analysis examines offering genomic newborn screening privately while public programs catch up, the exact gap Fore fills today. It argues that responsible private screening can extend benefits to families now, alongside public newborn screening.

This review explains how next-generation sequencing lets a single sample screen for many conditions at once, well beyond traditional biochemical tests. It describes the core technology Fore uses to assess 1,000+ genes from one at-home cheek swab.

The paper maps the ethical, legal, and social questions raised by genomic newborn screening and how to handle them responsibly. It informs how Fore returns results carefully, with counseling and strong privacy safeguards.

Young adults reflecting on newborn genetic results valued learning early about medically actionable conditions. This supports Fore’s focus on actionable, treatable childhood conditions where early knowledge can change outcomes.

This history traces newborn screening from the single PKU test to multi-condition genome sequencing. It positions Fore’s DNA-based screen as the natural next step beyond the limited standard panel.

Examines how the U.S. can modernize newborn screening using new sequencing technologies. It supports expanding beyond today’s 30–80 condition state panels, the gap Fore is built to close.

Shows that pairing sequencing with traditional biochemical screening improves accuracy and widens the range of conditions detected. It validates a layered model in which genomic screening like Fore’s complements standard newborn screening.